» Articles » PMID: 28296720

Usefulness of AFP, AFP-L3, and PIVKA-II, and Their Combinations in Diagnosing Hepatocellular Carcinoma

Overview
Specialty General Medicine
Date 2017 Mar 16
PMID 28296720
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

Alpha-fetoprotein (AFP), Lens culinaris-agglutinin-reactive fraction of AFP (AFP-L3), and protein induced by vitamin K absence or antagonist-II (PIVKA-II) are widely used as tumor markers for the diagnosis of hepatocellular carcinoma (HCC). This study compared the diagnostic values of AFP, AFP-L3, and PIVKA-II individually and in combination to find the best biomarker or biomarker panel.Seventy-nine patients with newly diagnosed HCC and 77 non-HCC control patients with liver cirrhosis were enrolled. AFP, AFP-L3, and PIVKA-II were measured in the same serum samples using microchip capillary electrophoresis and a liquid-phase binding assay on an automatic analyzer. Receiver-operating characteristic curve analyses were also applied to all combinations of the markers.When the 3 biomarkers were analyzed individually, AFP showed the largest area under the receiver-operating characteristic curve (AUC) (0.751). For combinations of the biomarkers, the AUC was highest (0.765) for "PIVKA-II > 40 mAU/mL and AFP > 10 ng/mL." The combination of "PIVKA-II > 40 mAU/mL and AFP > 10 ng/mL and AFP-L3 > 10%" had worse sensitivity and lower AUC (P = 0.001). The highest AUC of a single biomarker was highest for AFP and of a combination was "PIVKA-II > 40 mAU/mL and AFP > 10 ng/mL," with this also being the case when the cut-off value of AFP and AFP-L3 was changed.Alpha-fetoprotein showed the best diagnostic performance as a single biomarker for HCC. The diagnostic value of AFP was improved by combining it with PIVKA-II, but adding AFP-L3 did not contribute to the ability to distinguish between HCC and non-HCC liver cirrhosis. These findings were not altered when the cut-off value of AFP and AFP-L3 was changed.

Citing Articles

The Diagnostic Performance of AFP, AFP-L3, DCP, CA199, and Their Combination for Primary Liver Cancer.

Liu Y, Jiang W, Li X, Zhao H, Wang S J Hepatocell Carcinoma. 2025; 12:513-526.

PMID: 40065840 PMC: 11892369. DOI: 10.2147/JHC.S499966.


Strategies for discovering novel hepatocellular carcinoma biomarkers.

Wu S, Zhu L, Feng X, Wang H, Li F World J Hepatol. 2025; 17(2):101201.

PMID: 40027561 PMC: 11866143. DOI: 10.4254/wjh.v17.i2.101201.


Coilin Affects the Prognosis of Hepatocellular Carcinoma Through Cell Cycle and Apoptosis.

Lu L, Zhou X, Zheng J, Li D J Hepatocell Carcinoma. 2025; 12:367-382.

PMID: 40008396 PMC: 11853879. DOI: 10.2147/JHC.S500119.


Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies.

Hou J, Berg T, Vogel A, Piratvisuth T, Trojan J, De Toni E JHEP Rep. 2025; 7(2):101263.

PMID: 39897614 PMC: 11782856. DOI: 10.1016/j.jhepr.2024.101263.


Unlocking the diagnostic potential of vascular endothelial growth factor and interleukin-17: Advancing early detection strategies for hepatocellular carcinoma.

Subramanian S, Rajakumar H World J Gastrointest Surg. 2024; 16(11):3639-3642.

PMID: 39649218 PMC: 11622092. DOI: 10.4240/wjgs.v16.i11.3639.


References
1.
Lok A, Sterling R, Everhart J, Wright E, Hoefs J, Di Bisceglie A . Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2009; 138(2):493-502. PMC: 2819612. DOI: 10.1053/j.gastro.2009.10.031. View

2.
Youk C, Choi M, Paik S, Ahn B, Lee J, Koh K . [Early diagnosis and improved survival with screening for hepatocellular carcinoma]. Taehan Kan Hakhoe Chi. 2003; 9(2):116-23. View

3.
Liebman H, Furie B, Tong M, BLANCHARD R, Lo K, Lee S . Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984; 310(22):1427-31. DOI: 10.1056/NEJM198405313102204. View

4.
Chaiteerakij R, Addissie B, Roberts L . Update on biomarkers of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013; 13(2):237-45. PMC: 4032371. DOI: 10.1016/j.cgh.2013.10.038. View

5.
Kim M, Kim B, Han K . Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol. 2013; 48(6):681-8. PMC: 3698419. DOI: 10.1007/s00535-013-0770-9. View